Israel Englander Nektar Therapeutics Transaction History

Millennium Management LLC

$207 Billion
Q2 2024

A detailed history of Israel Englander (Millennium Management LLC) transactions in Nektar Therapeutics stock. As of the latest transaction made, Millennium Management LLC holds 4,659,469 shares of NKTR stock, worth $6.48 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

4,659,469

Previous 2,984,545 56.12%

Holding current value

$6.48 Million

Previous $2.78 Million 108.18%

% of portfolio

0.0%

Previous 0.0%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$0.9 - $1.83 $1.51 Million - $3.07 Million	1,674,924 Added 56.12%	4,659,469 $5.78 Million
Q1 2024 May 15, 2024	BUY	$0.49 - $0.96 $680,314 - $1.33 Million	1,388,396 Added 86.98%	2,984,545 $2.78 Million
Q4 2023 Feb 14, 2024	SELL	$0.42 - $0.57 $1.21 Million - $1.64 Million	-2,874,669 Reduced 64.3%	1,596,149 $893,000
Q2 2023 Aug 14, 2023	BUY	$0.53 - $1.03 $2.34 Million - $4.55 Million	4,414,571 Added 7848.54%	4,470,818 $2.59 Million
Q1 2023 May 15, 2023	SELL	$0.64 - $3.15 $356,263 - $1.75 Million	-556,662 Reduced 90.82%	56,247 $40,000
Q4 2022 Feb 14, 2023	BUY	$2.03 - $4.28 $922,630 - $1.95 Million	454,498 Added 286.91%	612,909 $1.39 Million
Q3 2022 Nov 14, 2022	BUY	$3.04 - $5.14 $481,569 - $814,232	158,411 New	158,411 $507,000
Q2 2022 Aug 15, 2022	SELL	$3.17 - $6.17 $5.88 Million - $11.4 Million	-1,854,623 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$4.16 - $13.72 $2.55 Million - $8.42 Million	613,920 Added 49.48%	1,854,623 $10 Million
Q4 2021 Feb 14, 2022	BUY	$10.83 - $18.41 $6.32 Million - $10.7 Million	583,750 Added 88.86%	1,240,703 $16.8 Million
Q3 2021 Nov 15, 2021	BUY	$13.07 - $18.84 $1.05 Million - $1.52 Million	80,564 Added 13.98%	656,953 $11.8 Million
Q2 2021 Aug 16, 2021	BUY	$16.52 - $20.4 $7.74 Million - $9.56 Million	468,486 Added 434.17%	576,389 $9.89 Million
Q1 2021 May 17, 2021	SELL	$16.56 - $25.46 $8.49 Million - $13.1 Million	-512,935 Reduced 82.62%	107,903 $2.16 Million
Q4 2020 Feb 16, 2021	BUY	$15.77 - $19.03 $8.03 Million - $9.69 Million	509,165 Added 455.94%	620,838 $10.6 Million
Q3 2020 Nov 16, 2020	BUY	$16.59 - $24.79 $301,622 - $450,706	18,181 Added 19.45%	111,673 $1.85 Million
Q2 2020 Aug 14, 2020	SELL	$16.86 - $23.44 $682,543 - $948,921	-40,483 Reduced 30.22%	93,492 $2.17 Million
Q1 2020 May 14, 2020	SELL	$14.47 - $27.96 $7.5 Million - $14.5 Million	-518,445 Reduced 79.46%	133,975 $2.39 Million
Q4 2019 Feb 14, 2020	SELL	$15.87 - $23.12 $5.36 Million - $7.81 Million	-337,678 Reduced 34.11%	652,420 $14.1 Million
Q3 2019 Nov 14, 2019	BUY	$16.91 - $36.27 $16.7 Million - $35.9 Million	990,098 New	990,098 $18 Million
Q4 2018 Feb 14, 2019	SELL	$30.43 - $56.65 $25.8 Million - $48.1 Million	-848,202 Closed	0 $0
Q3 2018 Nov 14, 2018	SELL	$46.46 - $68.49 $28.8 Million - $42.5 Million	-620,391 Reduced 42.24%	848,202 $51.7 Million
Q2 2018 Aug 14, 2018	BUY	$46.25 - $104.45 $18.1 Million - $40.9 Million	391,765 Added 36.38%	1,468,593 $71.7 Million
Q1 2018 May 15, 2018	BUY	$57.4 - $108.44 $61.8 Million - $117 Million	1,076,828 New	1,076,828 $114 Million

Others Institutions Holding NKTR

# of Institutions

141

Shares Held

134M

Call Options Held

32.8K

Put Options Held

55.5K

View Full List

About NEKTAR THERAPEUTICS

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $260M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

More about NKTR

Track Israel Englander's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.

Account